Which has preferable earnings and valuation, GSK or NVS?

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.42 $7.54B $3.85 13.36 Novartis $54.53B 5.28 $13.98B $6.98 21.62

Is GSK or NVS more profitable?

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Novartis 24.87% 38.82% 15.16%

Does the media prefer GSK or NVS?

In the previous week, Novartis had 2 more articles in the media than GSK. MarketBeat recorded 10 mentions for Novartis and 8 mentions for GSK. Novartis' average media sentiment score of 1.26 beat GSK's score of 0.24 indicating that Novartis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Novartis 8 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, GSK or AZN?

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.42 $7.54B $3.85 13.36 Astrazeneca $58.74B 4.44 $10.23B $6.66 25.27

Is GSK or AZN more profitable?

GSK has a net margin of 17.82% compared to Astrazeneca's net margin of 17.19%. GSK's return on equity of 44.28% beat Astrazeneca's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Astrazeneca 17.19% 30.86% 12.68%

Does the media prefer GSK or AZN?

In the previous week, Astrazeneca had 56 more articles in the media than GSK. MarketBeat recorded 64 mentions for Astrazeneca and 8 mentions for GSK. Astrazeneca's average media sentiment score of 0.47 beat GSK's score of 0.24 indicating that Astrazeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Astrazeneca 37 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 8 Negative mention(s) 8 Very Negative mention(s) Neutral

Which has better valuation & earnings, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $327.80B 0.69 $15.51B $4.26 11.87 GSK $43.07B 2.42 $7.54B $3.85 13.36

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% GSK 17.82% 44.28% 11.49%

Does the media prefer NVO or GSK?

In the previous week, Novo Nordisk A/S had 24 more articles in the media than GSK. MarketBeat recorded 32 mentions for Novo Nordisk A/S and 8 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.71 beat GSK's score of 0.24 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 22 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, GSK or SNY?

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.42 $7.54B $3.85 13.36 Sanofi $47.35B 2.24 $8.84B $3.58 12.20

Is GSK or SNY more profitable?

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Sanofi 16.95% 13.39% 7.58%

Does the media prefer GSK or SNY?

In the previous week, Sanofi had 2 more articles in the media than GSK. MarketBeat recorded 10 mentions for Sanofi and 8 mentions for GSK. Sanofi's average media sentiment score of 0.73 beat GSK's score of 0.24 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ARGX or GSK?

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.63 $1.29B $22.46 38.42 GSK $43.07B 2.42 $7.54B $3.85 13.36

Is ARGX or GSK more profitable?

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% GSK 17.82% 44.28% 11.49%

Does the media refer more to ARGX or GSK?

In the previous week, GSK had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for GSK and 7 mentions for argenex. argenex's average media sentiment score of 1.18 beat GSK's score of 0.24 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

GSK (GSK) Competitors

$51.44 +0.19 (+0.38%)

Closing price 07/15/2026 03:59 PM Eastern

Extended Trading

$51.50 +0.06 (+0.11%)

As of 07/15/2026 07:41 PM Eastern

Compare

GSK vs. NVS, AZN, NVO, SNY, and ARGX

Should you buy GSK stock or one of its competitors? MarketBeat compares GSK with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GSK include Novartis (NVS), Astrazeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), and argenex (ARGX). These companies are all part of the "pharmaceutical products" industry.

How does GSK compare to Novartis?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novartis	24.87%	38.82%	15.16%

15.7% of GSK shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.42	$7.54B	$3.85	13.36
Novartis	$54.53B	5.28	$13.98B	$6.98	21.62

In the previous week, Novartis had 2 more articles in the media than GSK. MarketBeat recorded 10 mentions for Novartis and 8 mentions for GSK. Novartis' average media sentiment score of 1.26 beat GSK's score of 0.24 indicating that Novartis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novartis	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK currently has a consensus price target of $53.00, indicating a potential upside of 3.03%. Novartis has a consensus price target of $141.20, indicating a potential downside of 6.42%. Given GSK's higher possible upside, analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays out 46.5% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Summary

Novartis beats GSK on 13 of the 18 factors compared between the two stocks.

How does GSK compare to Astrazeneca?

GSK (NYSE:GSK) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.42	$7.54B	$3.85	13.36
Astrazeneca	$58.74B	4.44	$10.23B	$6.66	25.27

GSK has a net margin of 17.82% compared to Astrazeneca's net margin of 17.19%. GSK's return on equity of 44.28% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Astrazeneca	17.19%	30.86%	12.68%

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. GSK pays out 46.5% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

15.7% of GSK shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GSK has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, Astrazeneca had 56 more articles in the media than GSK. MarketBeat recorded 64 mentions for Astrazeneca and 8 mentions for GSK. Astrazeneca's average media sentiment score of 0.47 beat GSK's score of 0.24 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Astrazeneca	37 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	8 Negative mention(s)	8 Very Negative mention(s)	Neutral

GSK currently has a consensus price target of $53.00, indicating a potential upside of 3.03%. Astrazeneca has a consensus price target of $211.00, indicating a potential upside of 25.40%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10
Astrazeneca	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Astrazeneca beats GSK on 12 of the 18 factors compared between the two stocks.

How does GSK compare to Novo Nordisk A/S?

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Novo Nordisk A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$327.80B	0.69	$15.51B	$4.26	11.87
GSK	$43.07B	2.42	$7.54B	$3.85	13.36

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
GSK	17.82%	44.28%	11.49%

Novo Nordisk A/S pays an annual dividend of $1.74 per share and has a dividend yield of 3.4%. GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Novo Nordisk A/S pays out 40.8% of its earnings in the form of a dividend. GSK pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Novo Nordisk A/S presently has a consensus price target of $65.56, indicating a potential upside of 29.66%. GSK has a consensus price target of $53.00, indicating a potential upside of 3.03%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	2 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.13
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

In the previous week, Novo Nordisk A/S had 24 more articles in the media than GSK. MarketBeat recorded 32 mentions for Novo Nordisk A/S and 8 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.71 beat GSK's score of 0.24 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	22 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Novo Nordisk A/S beats GSK on 13 of the 18 factors compared between the two stocks.

How does GSK compare to Sanofi?

GSK (NYSE:GSK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

15.7% of GSK shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GSK currently has a consensus price target of $53.00, suggesting a potential upside of 3.03%. Sanofi has a consensus price target of $49.50, suggesting a potential upside of 13.32%. Given Sanofi's stronger consensus rating and higher probable upside, analysts plainly believe Sanofi is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.42	$7.54B	$3.85	13.36
Sanofi	$47.35B	2.24	$8.84B	$3.58	12.20

GSK pays an annual dividend of $1.79 per share and has a dividend yield of 3.5%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. GSK pays out 46.5% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Sanofi	16.95%	13.39%	7.58%

In the previous week, Sanofi had 2 more articles in the media than GSK. MarketBeat recorded 10 mentions for Sanofi and 8 mentions for GSK. Sanofi's average media sentiment score of 0.73 beat GSK's score of 0.24 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Summary

GSK beats Sanofi on 10 of the 18 factors compared between the two stocks.

How does GSK compare to argenex?

argenex (NASDAQ:ARGX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

argenex has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

argenex has a net margin of 31.31% compared to GSK's net margin of 17.82%. argenex's return on equity of 44.37% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
GSK	17.82%	44.28%	11.49%

In the previous week, GSK had 1 more articles in the media than argenex. MarketBeat recorded 8 mentions for GSK and 7 mentions for argenex. argenex's average media sentiment score of 1.18 beat GSK's score of 0.24 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex currently has a consensus target price of $1,037.61, indicating a potential upside of 20.24%. GSK has a consensus target price of $53.00, indicating a potential upside of 3.03%. Given argenex's stronger consensus rating and higher possible upside, equities research analysts plainly believe argenex is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

60.3% of argenex shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GSK has higher revenue and earnings than argenex. GSK is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.63	$1.29B	$22.46	38.42
GSK	$43.07B	2.42	$7.54B	$3.85	13.36

Summary

argenex beats GSK on 13 of the 17 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$103.66B	$3.65B	$6.78B	$23.40B
Dividend Yield	3.49%	2.22%	2.68%	4.02%
P/E Ratio	13.37	21.32	27.08	31.19
Price / Sales	2.42	178.51	487.23	74.46
Price / Cash	8.53	143.89	48.63	32.25
Price / Book	4.98	8.56	10.82	4.78
Net Income	$7.54B	$23.88M	$3.59B	$1.07B
7 Day Performance	-2.04%	-3.25%	-1.80%	0.52%
1 Month Performance	-1.55%	7.59%	3.71%	0.54%
1 Year Performance	34.44%	49.87%	27.41%	18.39%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	2.9705 of 5 stars	$51.44 +0.4%	$53.00 +3.0%	+36.0%	$103.66B	$43.07B	13.37	66,841	Dividend Cut
NVS Novartis	2.7431 of 5 stars	$151.42 -1.3%	$141.20 -6.8%	+26.1%	$288.66B	$54.53B	21.67	75,267	Positive News Upcoming Earnings
AZN Astrazeneca	4.617 of 5 stars	$165.75 -2.2%	$211.00 +27.3%	+19.6%	$257.03B	$58.74B	24.88	96,100	Trending News Analyst Downgrade
NVO Novo Nordisk A/S	4.2838 of 5 stars	$48.92 -0.7%	$65.56 +34.0%	-24.9%	$217.95B	$46.80B	11.46	69,505	Trending News Analyst Downgrade
SNY Sanofi	4.087 of 5 stars	$43.23 -1.8%	$49.50 +14.5%	-9.2%	$104.81B	$49.35B	12.08	74,846

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GSK) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors